Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel.
Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, Lin Y, Lunning MA, Hill BT, Ghobadi A, Hu ZH, Hemmer MT, Zoratti MJ, Vunnum S, Tsang J, Spooner C, Smith H, Fu C, Patel AR, Miao H, Shahani SA, Mirjah DL, Xu H, Pasquini MC.
Locke FL, et al. Among authors: xu h.
Blood Adv. 2025 Jan 30:bloodadvances.2024013656. doi: 10.1182/bloodadvances.2024013656. Online ahead of print.
Blood Adv. 2025.
PMID: 39883946